S. Bilic

发表

American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates

B. Meibohm, Hong Zhao, H. Erickson, 2013, mAbs.

Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia

J. Byrd, I. Flinn, T. Kipps, 2012, Leukemia & lymphoma.

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma

M. Pike, M. Beckmann, P. Fasching, 2021, Virchows Archiv.

Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors

Jeffrey W. Scott, Sunil Sharma, H. Burris, 2014, Investigational New Drugs.

New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats

O. Heudi, M. Walles, T. Moenius, 2016, Drug Metabolism and Disposition.

Bmc Clinical Pharmacology Renal Safety of Zoledronic Acid with Thalidomide in Patients with Myeloma: a Pharmacokinetic and Safety Sub-study

S. Cremers, A. Roberts, H. Schran, 2022 .

Phase I trial of LBY135, a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors

de Elisabeth G. E. Vries, Jeffrey W. Scott, H. Burris, 2008 .

PERIPHERALLY-DERIVED AUTOLOGOUS T CELL THERAPY IN SOLID TUMOR PATIENTS

Shawn P. Carey, J. Fitzgerald, A. Shields, 2020 .

Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk‐Benefit Approach

J. Bullock, Tiffany Lin, S. Bilic, 2017, Journal of clinical pharmacology.

Spatial transcriptomics reveals ovarian cancer subclones with distinct tumour microenvironments

A. Forrest, E. Denisenko, E. Gray, 2022, bioRxiv.

A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases

Kylie L. Gorringe, A. Talhouk, R. Vierkant, 2019, Modern Pathology.

Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies

R. Mosher, W. Sellers, P. Finan, 2010, Proceedings of the National Academy of Sciences.

A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy

Kimberly S. Long, A. Kalra, J. Still, 2021, Advances in Therapy.

Pharmacokinetics and Pharmacodynamics from a First-in-Human Phase 1 Dose Escalation Study with Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12), in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.

J. Byrd, I. Flinn, T. Kipps, 2006 .

Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction

W. Sellers, Guizhi Yang, C. Kowal, 2014, mAbs.

Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers.

W. Sellers, T. Hu, Vivien W. Chan, 2017, Cancer discovery.

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Kylie L. Gorringe, S. Fox, P. Fasching, 2020, Modern Pathology.

Transcriptomic analysis of patient plasma reveals circulating miR200c as a potential biomarker for high-grade serous ovarian cancer

P. Cohen, C. Whitehead, N. Hannan, 2021, Gynecologic oncology reports.

Excisional treatment comparison for in situ endocervical adenocarcinoma (EXCISE): A phase 2 pilot randomized controlled trial to compare histopathological margin status, specimen size and fragmentation after loop electrosurgical excision procedure and cold knife cone biopsy.

Ai Ling Tan, M. Stockler, M. Bulsara, 2020, Gynecologic oncology.

Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor

K. Papadopoulos, D. Rasco, Heather A. Huet, 2015, Cancer Chemotherapy and Pharmacology.

Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors

David J. Chen, J. Lansita, A. Kalra, 2021, International journal of toxicology.

A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12) in Patients with Relapsed and Refractory Multiple Myeloma.

S. Jagannath, S. Girish, A. Solinger, 2006 .

Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer

K. Byth, S. Fox, S. Lade, 2014, Scientific Reports.

Preparing pharmacy graduates for traditional and emerging career opportunities.

S. Meyer, R. Nemire, E. F. Fiese, 2009, American journal of pharmaceutical education.

Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome

F. Giles, G. Roboz, M. Schuster, 2006, Leukemia.

A Phase IB multicentre dose‐determination study of BHQ880 in combination with anti‐myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal‐related events

N. Munshi, A. Stewart, J. Shah, 2014, British journal of haematology.

TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members

Dale W. Garsed, Kenneth D. Doig, L. Andrews, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1 study of lucatumumab, a fully human anti‐CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma

S. Jagannath, B. Ewald, R. Maziarz, 2012, British journal of haematology.

A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.

J. Schellens, J. Soria, Sunil Sharma, 2016 .

OR03-2 Phase 1, Randomized, Controlled Trial of GFB-024, a Once-Monthly CB1 Inverse Agonist, in Healthy Overweight and Obese Participants and in Participants with Type 2 Diabetes Mellitus

Y. Dagon, G. Gaich, Leslie Johnson, 2022, Journal of the Endocrine Society.

392-P: Phase 1, Randomized, Controlled Trial of GFB-024, a Once-Monthly CB1 Inverse Agonist, in Healthy Overweight and Obese Participants and in Participants with Type 2 Diabetes Mellitus

Y. Dagon, G. Gaich, Leslie Johnson, 2022, Diabetes.

Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression

S. Jagannath, S. Lonial, D. Siegel, 2012 .

Abstract 3853: TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches

W. Sellers, S. Fawell, D. Stover, 2012 .

Future Pharmacy Graduates - Making More Opportunities Than We See White Paper Prepared for the American Association of Colleges of Pharmacy (AACP) Curricular Change Summit March 2009 Authors:

S. Meyer, J. Bullock, G. Brazeau, 2009 .

A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma

S. Lonial, P. Richardson, S. Horwitz, 2021, Blood.

Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper.

Surinder Kaur, Shobha Purushothama, Sanela Bilic, 2013, Bioanalysis.

A phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (Pts) with stage IC to IV epithelial ovarian cancer (EOC).

P. Viens, A. du Bois, P. Witteveen, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx).

N. Munshi, A. Dzik-Jurasz, F. Giles, 2009 .

A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases

Kylie L. Gorringe, A. Talhouk, R. Vierkant, 2019, Modern Pathology.